An integrated interdisciplinary approach to animal-free nanomaterial and chemical safety assessment.

:: home ::   :: project background ::     :: sub projects ::      :: work plan ::       :: training ::      :: apply here ::         -> back to ESTIV

The in3 project is funded by the EU's Marie Skłodowska-Curie Action - Innovative Training Network (MSCA-ITN for short)  that aims to drive the synergistic development and utilisation of in vitro and in silico tools for human chemical and nanomaterial (NM) safety assessment. The project will focus on differentiation of human induced Pluripotent Stem Cells (hiPSC) to toxicologically relevant target tissues including; brain, lung, liver and kidney. The tissues, from the same genetic backgrounds, will be exposed to several compounds and the data generated will be used to develop safety assessment approaches by integrating cheminformatics, mechanistic toxicology and biokinetics into computational models. The project will hire 15 PhD students to carry out these activities in a coordinated and highly collaborative fashion.  The scientists trained within in3 will acquire a unique multidisciplinary skill set giving them a competitive employment advantage in safety assessment sciences either in industry, governmental bodies or academia.

Core scientific activities:

  • Differentiation of well-characterised human iPSC into brain, lung, liver, kidney and vascular cells

  • Delineation of tissue specific and donor specific effects of compound exposures (uptake, metabolism, extrusion, and mechanistic toxicity)

  • Development and optimisation of quantitative adverse outcome pathways (qAOPs) for each target organ which will be unified in an organism-level model

  • Optimisation of QSAR and read-across tools for safety assessment

  • Ultimately to create a  unified expandable integrated testing strategy for chemical and NM safety assessment

For individual projects click here.

in3 Consortium Beneficiaries (Hosts) and Partner Organisations


Medizinische Universität Innsbruck, Austria. Physiology and Medical Physics/Physiology, Ass. Prof. Paul Jennings. Coordinator.
Evercyte GmbH, Austria. Prof. Regina Grillari
Université d’Artois, France. BBB Laboratory. Ass Prof. Maxime Culot
University of Lausanne, Switzerland. Physiology. Marie-Gabrielle Zurich
BIOTALENTUM, Hungary. Prof. Andras Dinnyes
University of Leuven, Leuven, Belgium.  KU Leuven Stem Cell Institute,  Prof. Catherine Verfaillie
Department of Health – Public Health England, United Kingdom. Toxicology Dept./Centre for Radiation, Chemical and Environmental Hazards/Nanotoxicology Laboratory. Dr. Martin Leonard.
Newcells Biotech, United Kingdom. Prof. Lyle Armstrong
Istituto di Ricerche Farmacologiche Mario Negri, Italy. Environmental Health Sciences/Laboratory of Environmental Chemistry and Toxicology. Prof. Emilio Benfenati
Liverpool John Moores University, United Kingdom. School of Pharmacy and Biomolecular Sciences. Prof. Mark Cronin
National Institute of Chemistry, Ljubljana, Slovenia. Laboratory of Chemometrics. Prof. Marjana Novič
Universiteit Utrecht, The Netherlands. Institute for Risk Assessment Sciences/Toxicology. Ass. Prof. Nynke Kramer
Douglas Connect, Switerland. Dr. Barry Hardy

Partner Organisations

Center for Alternatives to Animal Testing – EUROPE, Universität Konstanz, Germany. Dr. Mardas Daneshian
European Union Reference Laboratory for alternatives to animal testing, Italy. Institute for Health and Consumer Protection, European Commission Joint Research Centre. Dr. Anna Price
European Society of Toxicology in vitro, The Netherlands. Prof. Mathieu Vinken
Nanocomposix Europe, Czech Republic. Dr. Pavel Tucek
L’Oreal, France. Gladys Ouedraogo


Follow us on twitter: in3@in3.itn


in3 is funded by the Marie Skłodowska-Curie Action - Innovative Training Network under grant no. 721975.